Cardiovascular disease (CVD) is one of the major causes of death worldwide, accounting for ~37% of global annual premature deaths due to non-communicable diseases. CVDs are usually associated with damage to large arteries and arteries in vital organs such as the heart, brain, and kidney.

Early detection, timely intervention, and efficient disease management is the best way to control CVDs and thereby reduce its risk for future adverse events.

Primary prevention strategies and most risk prediction methods for CVD currently use traditional risk factors such as hypertension, diabetes, dyslipidemia, and tobacco toxins. Their overall predictive performance, however, is suboptimal, and miss the early signs of vascular aging and disease progression that alter vascular properties even decades before dysregulation of conventional markers.

In the early stages of the disease, before the conventional markers get deranged, they initiate and promote structural changes in major arteries by impairing functions of the endothelium (the interior surface of blood vessels) and stiffening the central elastic arteries. Therefore, a combined assessment of early vascular physiological markers, viz. Large Artery Local Stiffness, Central-to-Peripheral Regional Vascular Stiffness, Vascular Age, and Central Arterial Blood Pressure offer a unique view of the underlying disease progression and more reliable estimates of the cumulative burden of future risks.

These non-invasive measures also provide a unique ability for risk assessment and following-up patients on the effects of medication and lifestyle changes and are increasingly explored by the research community for the validation of novel strategies for risk stratification.

Despite the solid background and strong scientific support, the need for ultrasound imaging devices supplemented by customized image analysis modules and expertise to perform measurements have prevented wide-spread adoption of these highly useful early vascular health markers. Such specific devices have not extensively infiltrated clinical practice.

ARTSENS^® is a patented image-free ultrasound technology for comprehensive assessment of early vascular health markers and central blood pressure parameters.
Intelligent algorithms of ARTSENS® enable fully automated measurements in an easy-to-use manner, thereby eliminating the need for imaging equipment, expert operator, prolonged screening, and offline processing.
This clinically validated technology is ideal for routine clinical practice, field-level evaluation, and large-scale screening applications.

ARTSENS^®Pen is a miniaturised hand-held device (Size = 18 cm × 3 cm × 2.5 cm; Weight = 55 g) equipped with a lightweight Vascular Probe to perform local stiffness measurement from the common carotid artery (viz. Pressure-strain elastic modulus, Arterial Compliance, Specific vascular stiffness index-β, and One-point local pulse wave velocity).

ARTSENS^® Plus is the most evolved portable device (Size = 24 cm × 17 cm × 6 cm; Weight = 950 g) equipped with a Vascular Probe and cuffs (upper-arm and thigh) to perform combined and simultaneous measurement of cal pulse wave velocity.

1. Local stiffness from the common carotid artery (viz. Pressure-strain elastic modulus, Arterial Compliance, Specific vascular stiffness index-β, One-point local (diastolic and systolic) pulse wave velocity, and Incremental pulse wave velocity)

2. Regional stiffness (Carotid-femoral pulse wave velocity)

3. Central blood pressure parameters from the common carotid artery (viz. carotid systolic, diastolic, and mean arterial pressure values)

Devices can be directly connected to any Microsoft Windows based computer/laptop/tablet, without an external power source, to perform real-time measurements.

It generates a custom clinical report, and provides options for data saving and exporting the raw measurements (for research applications).